BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:VH4524184 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of VH4524184\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07202546-978@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:VH4524184: Phase 2 readout est. (NCT07202546)
DESCRIPTION:VH4524184\, phase 2\, HIV.\nStudy: A Phase 2b Study Evaluating 
 Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE S
 tudy)\nEstimated primary completion: 28 October 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/vh4524184#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07202546
URL:https://assetmemo.bio/drug/vh4524184#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06310551-978@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20290528
DTEND;VALUE=DATE:20290529
SUMMARY:VH4524184: Phase 1 readout est. (NCT06310551)
DESCRIPTION:VH4524184\, phase 1\, HIV.\nStudy: First Time in Human Study of
  Long Acting VH4524184 Formulations\nEstimated primary completion: 28 May 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/vh4524184#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06310551
URL:https://assetmemo.bio/drug/vh4524184#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
